Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 60

recruiting
3 972
countries
28
conditions
2 103

1 070 trials match your criteria

Neuroblastoma+1

Not recruiting

Study of Palbociclib with Drug Combinations for Children and Young Adults with Recurrent or Refractory Neuroblastoma and Ewing Sarcoma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years
  • Substances:Palbociclib

Emphysema

Not recruiting

Study on Long-term Safety of Weekly Intravenous Alpha-1-Proteinase Inhibitor for Patients with Pulmonary Emphysema Due to Alpha-1-Antitrypsin Deficiency

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:ALPHA-1-PROTEINASE inhibitor (human)

Emphysema

Not recruiting

Study on the Effects of Alpha-1-Proteinase Inhibitor for Patients with Pulmonary Emphysema Due to Alpha-1 Antitrypsin Deficiency

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:ALPHA-1-PROTEINASE inhibitor (human)

Demyelination

Not recruiting

Study on the Effectiveness and Safety of Rozanolixizumab for Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOG-AD)

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Rozanolixizumab

Cholangiocarcinoma

Not recruiting

Study Comparing Pemigatinib and Gemcitabine Plus Cisplatin for First-Line Treatment in Patients with Unresectable or Metastatic Cholangiocarcinoma with FGFR2 Rearrangement

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin

Idiopathic pulmonary fibrosis+1

Not recruiting

Study on BI 1839100 for Reducing Cough in Patients with Idiopathic or Progressive Pulmonary Fibrosis

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:BI 1839100

Plasma cell myeloma

Not recruiting

Study Comparing Teclistamab, Talquetamab, and Drug Combination for Patients with Newly Diagnosed Multiple Myeloma Not Suitable for Stem Cell Transplant

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab

Schizophrenia

Not recruiting

Study on Rituximab for Adults with Schizophrenia Spectrum Disorder

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Rituximab

Heart failure with reduced ejection fraction+1

Not recruiting

Study on the Effects of AZD3427 on Kidney Function in Heart Failure Patients with Kidney Issues

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:AZD3427

Plasma cell myeloma

Not recruiting

Study of Belantamab Mafodotin Alone and with Drug Combination for Patients with Relapsed/Refractory Multiple Myeloma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin

Idiopathic pulmonary fibrosis

Not recruiting

Study on BI 1819479 to Improve Lung Function in Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:BI 1819479

Osteogenesis imperfecta

Not recruiting

Study on the Safety and Effectiveness of BOOST Cells for Treating Severe Osteogenesis Imperfecta in Children Before and After Birth

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years
  • Substances:Allogeneic Fetal Mesenchymal Stem Cells

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.